Ignite Creation Date:
2024-05-06 @ 2:49 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02134717
Status:
TERMINATED
Last Update Posted:
2018-02-14
First Post:
2014-04-30
Brief Title:
Impact of Chemokine Receptor 5 CCR5 Inhibition on Sarcoidosis Immunophenotypes
Sponsor:
Kevin F Gibson
Organization:
University of Pittsburgh
Study Overview
Official Title:
An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis
Status:
TERMINATED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Poor recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GRADS
Brief Summary:
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis Subjects with active sarcoidosis will first undergo bronchoscopy with bronchoalveolar lavage to recover lung immune cells for baseline analysis They will then receive the drug maraviroc for 6 weeks duration They will then undergo a repeat bronchoscopy with bronchoalveolar lavage to recover lung immune cells for analysis following maraviroc treatment
Detailed Description:
The investigators hypothesize that inhibition of CCR5 by maraviroc may have a beneficial immunomodulatory effect on the granulomatous inflammation of pulmonary sarcoidosis The specific aim of this proposal is the investigate the effect of CCR5 inhibition on the trafficking of mononuclear cells to the lung skin peripheral blood in subjects with active sarcoidosis exposed to the CCR5 inhibitor maraviroc A second aim will be to isolate by cell sorting cluster of differentiation 4 CD4CCR5 T cells for amplified gene expression profiling before and after CCR5 inhibition experiments the investigators believe will elucidate genes associated with downstream activation and inhibition of CCR5 receptor function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None